Start here if you're new
what it is
It makes drugs that tell bad proteins to get broken down by the body.
how it gets paid
Last year Therapeutics made $36M in revenue. collaboration revenue was the main engine at $14M, or 39% of sales.
why it's growing
Revenue grew 1.0% last year. The 122% revenue jump mattered because it shows the top line can spike fast.
what just happened
Revenue hit $25M in the latest quarter, while EPS stayed deeply negative.
At a glance
C++ balance sheet — some cracks in the foundation
-$1.27 fy2025 eps est
$2B fy2026 rev est
n/a operating margin
2.2 beta
xvary composite: 20/100 — weak
What they do
It makes drugs that tell bad proteins to get broken down by the body.
You are buying a 104-person lab, not a factory. TORPEDO means Target Oriented Protein Degrader Optimizer, or a drug design system that tags disease proteins for cleanup. That matters because one clean Phase 1 readout can matter more than scale in biotech.
How they make money
$36M
annual revenue · their business grew +1.0% last year
collaboration revenue
$14M
milestone revenue
$11M
license revenue
$7M
other research revenue
$4M
The products that matter
lead oncology drug candidate
Cemsidomide
phase 1b expected in early 2026
this is the most advanced program in the pipeline, and the next meaningful step is a Phase 1b trial expected in early 2026. For a company with $36M in revenue, timeline execution matters almost as much as the data itself.
lead asset
drug discovery platform
TORPEDO Platform
engine behind the pipeline
this is the internal design engine for the company's protein-degradation programs. It may be the scientific foundation, but the market still sees a business that produced only $36M in revenue last year.
platform bet
balance sheet fuel
Cash Position
$297M on hand
for now, cash is effectively a product feature. At last year's $105M loss, this pile buys time, and time is what every clinical-stage biotech sells before it sells medicine.
runway
Key numbers
$36M
annual revenue
That is the whole business today. For a $265M market cap, you are paying a lot for a very small sales base.
n/a
op margin
Prior margin KPI failed sanity check — verify in filings. Jargon: operating margin, or profit before interest and taxes as a share of sales. So what: spending was more than three times revenue.
$54M
long-term debt
Debt is small versus the company size, but it still matters when losses are this wide.
2.2
beta
Beta is stock wiggle versus the market. At 2.2, this name can move about twice as hard as the market.
Financial health
C++
strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $54M (17% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total return vs. market
Return history isn't available for CCCC right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Revenue hit $25M in the latest quarter, while EPS stayed deeply negative.
EDGAR showed $25M of revenue in the latest quarter, up 122% vs. prior year. EPS was -$1.18, so the business still burned cash while revenue jumped.
$25M
revenue
-$1.18
eps
122%
revenue growth
the number that mattered
The 122% revenue jump mattered because it shows the top line can spike fast, even while losses stay ugly.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is cemsidomide failing to earn confidence in early-stage development.
med
Clinical disappointment
This is a $265M company with no approved products. If the lead asset does not show enough promise to justify Phase 1b and beyond, the current equity story loses its center of gravity.
Impact: the market is valuing optionality. If the option expires, a lot of the equity can go with it.
med
Cash runway compression
The company ended with $297M in cash after posting a $105M full-year loss. That is meaningful funding, but not endless funding, especially if trials get larger or timelines slip.
Impact: at last year's pace, the cash pile covers under three years. Biotech time moves slower than investor patience.
med
Better-funded competitors
C4 is competing in a field where peers are valued at $3.4B to $10.7B. Bigger balance sheets do not guarantee better science, but they do buy more shots on goal.
Impact: if similar programs advance faster elsewhere, this stock can get cheaper even without its own data getting worse.
med
Platform promise not turning into economics
The TORPEDO platform is the intellectual story, but the current business still generated only $36M in revenue. A good platform that never becomes repeatable economics is still just a story.
Impact: if partnership or pipeline traction stays thin, the market may keep valuing the company near cash rather than near future potential.
At last year's loss rate, $297M in cash buys time but not immunity. This is a binary stock with a balance-sheet buffer.
source: institutional data · regulatory filings · risk analysis
Pay attention to
timeline
Cemsidomide Phase 1b start
Management said early 2026. In a company this early, hitting the calendar is one of the few hard signals you get before clinical data shows up.
runway
Cash versus annual loss
$297M of cash against a $105M yearly loss is the ratio to watch. If that spread worsens, financing risk moves to the front of the page.
sentiment
Analyst target spread
Published targets range from $6 to $30. Same company. Same facts. That gap tells you the valuation is mostly probability, not math.
competition
Peer progress in protein degradation
Rivals worth $3.4B to $10.7B are chasing the same broad scientific opportunity. You do not need C4's data to worsen for the relative story to weaken.
Analyst rankings
risk profile
high risk
risk rank 5 — significant risk of large drawdowns.
chart momentum
bottom 5%
momentum rank 5 — the lowest rating — significant underperformance expected.
source: institutional data
Institutional activity
institutional ownership data for CCCC is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$4
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive